Plytle,

Agreed.The fact that Afrezza starts working in 12-15 minutes and is out of the body 2-3 hours later is what really sets it apart.By leaving the body so quickly it reduces or eliminates Hypoglycemia,a major cause of hospitalization and death.Then add the fact that it may slow down or stop the progression of the disease.Afrezza is in a class by itself.Now if we can only convince the FDA.

Al:

"For Type 2s, based on my understanding of the mechanism of the disease, AFREZZA may play an important role early in management of the disease. After all, the underlying deficit begins with the loss of prandial glucose control. As Peter noted, we intend to study this in finical trial not being planned. Early use of prandial insulins in Type 2 has not been pursued in the past, largely because of the deficiencies of current products. Yet many KOLs believe that there will an important role for earlier use of ultra-fast acting insulins that may even contribute to preventing progression of the disease."

http://seekingalpha.com/article/233332-mannkind-ceo-discusses-q3-2010-results-earnings-call-transcript?find=progression&all=false